SREBF2 and ovarian carcinoma: In vitro and in vivo experiments have revealed that SIK2 upregulated the sterol regulatory element binding protein 1c (SREBP1c) and sterol regulatory element binding protein 2 (SREBP2) expression via the PI3K/Akt signaling pathway, promoting major lipogenic enzyme fatty acid synthase (FASN) and cholesterol synthase hydroxy-3-methylglutaryl-CoA reductase (HMGCR) transcription, thereby enhancing fatty acid and cholesterol synthesis and contributing to ovarian cancer cell growth.